NCT05094947

Brief Summary

This is a prospective, comparative, multicenter, randomized controlled trial. The aim of this study is to compare the efficacy, safety and quality of life within patients with acute urinary retention managed by the intermittent catheterization compared or indwelling Foley catheter.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P75+ for not_applicable

Timeline
Completed

Started Aug 2021

Shorter than P25 for not_applicable

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 3, 2021

Completed
7 days until next milestone

First Submitted

Initial submission to the registry

August 10, 2021

Completed
3 months until next milestone

First Posted

Study publicly available on registry

October 26, 2021

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2022

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2022

Completed
Last Updated

October 26, 2021

Status Verified

August 1, 2021

Enrollment Period

7 months

First QC Date

August 10, 2021

Last Update Submit

October 15, 2021

Conditions

Keywords

Benign prostatic hyperplasiaacute urinary retentionintermittent catheterizationurethral cathetertrial without catheter

Outcome Measures

Primary Outcomes (1)

  • Assessment of the quality of life

    Assessment of the quality of life according to the SF-36 questionnaire on the first, second, or third day after the start of intermittent catheterization

    2 months

Secondary Outcomes (1)

  • Assessment of the restoration of self-urination.

    2 months

Study Arms (2)

intermittent catheterization (group B)

EXPERIMENTAL

Procedure/Surgery: The acute urinary retention in group B is managed by clean intermittent catheterization along with alpha-blockers during 3 period. After 3 days the ability of spontaneous voiding is assessed and registered as an outcome.

Procedure: intermittent catheterizationDrug: alpha-blockers

Catheter Foley (group A)

ACTIVE COMPARATOR

The acute urinary retention in group A is managed by trial without catheter along with alpha-blockers during 3 period. After 3 days the indwelling Foley catheter is removed and ability of spontaneous voiding is assessed and registered as an outcome.

Procedure: trial without catheterDrug: alpha-blockers

Interventions

clean intermittent catheterization with catheter Nelaton

intermittent catheterization (group B)

catheter Foley

Catheter Foley (group A)

tamsulosin, alfuzosin, doxazosin, silodosin

Catheter Foley (group A)intermittent catheterization (group B)

Eligibility Criteria

Age21 Years - 95 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Men with acute urinary retention due to prostatic hyperplasia

You may not qualify if:

  • Patient's with serious conditions and incapacity
  • Previous urethral or prostate surgery.
  • Urethral stricture.
  • Urethrorrhagia.
  • Injuries of urethra and perineum.
  • Attempts of bladder catheterization within 15 days before the acute urinary retention episode.
  • Urinary tract infection.
  • Neurogenic bladder.
  • Chronic urinary retention with a bladder volume of more than 1 liter.
  • Obstructive uropathy due to the acute urinary retention.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Moscow state university of medicine and dentistry named after A.I. Evdokimov

Moscow, 127473, Russia

RECRUITING

MeSH Terms

Conditions

Prostatic Hyperplasia

Interventions

Intermittent Urethral CatheterizationClinical Trials as TopicCathetersAdrenergic alpha-Antagonists

Condition Hierarchy (Ancestors)

Prostatic DiseasesGenital Diseases, MaleGenital DiseasesUrogenital DiseasesMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

Urinary CatheterizationCatheterizationTherapeuticsInvestigative TechniquesClinical Studies as TopicEpidemiologic Study CharacteristicsEpidemiologic MethodsHealth Care Evaluation MechanismsQuality of Health CareHealth Care Quality, Access, and EvaluationPublic HealthEnvironment and Public HealthEquipment and SuppliesAdrenergic AntagonistsAdrenergic AgentsNeurotransmitter AgentsMolecular Mechanisms of Pharmacological ActionPharmacologic ActionsChemical Actions and UsesPhysiological Effects of Drugs

Study Officials

  • Vigen Malkhasyan

    Moscow state university of medicine and dentistry named after A.I. Evdokimov

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 10, 2021

First Posted

October 26, 2021

Study Start

August 3, 2021

Primary Completion

March 1, 2022

Study Completion

May 1, 2022

Last Updated

October 26, 2021

Record last verified: 2021-08

Data Sharing

IPD Sharing
Will not share

Locations